Hypothesis

Restoring tropoelastin in aged arteries engages integrin αvβ3 on vascular smooth muscle cells (VSMCs) to activate a phosphatase‑dependent dephosphorylation cascade that suppresses Runx2 transcriptional activity, thereby blocking osteogenic transdifferentiation and simultaneously attenuating senescence‑associated secretory phenotype (SASP).

Rationale

• Tropoelastin declines with cellular senescence and its exogenous addition extends mesenchymal stromal cell replicative lifespan by suppressing CDKN1A/CDKN2A and dampening SASP [https://pmc.ncbi.nlm.nih.gov/articles/PMC11497112/].
• VSMCs switch to an osteoblast‑like phenotype via Runx2 upregulation, driven by PI3K/AKT, AGE/RAGE, and RANK/RANKL pathways under oxidative stress [https://pmc.ncbi.nlm.nih.gov/articles/PMC7199843/].
• Integrin αvβ3 is a known mechanosensor for extracellular matrix proteins and can modulate both AKT signaling and HDAC activity, influencing Runx2 nuclear localization and transcriptional competence.

Novel Mechanistic Insight

We propose that tropoelastin binding to integrin αvβ3 recruits the protein phosphatase PP2A to the integrin cytoplasmic tail. PP2A then dephosphorylates AKT at Ser473, reducing AKT‑mediated phosphorylation and nuclear retention of Runx2. Concurrently, integrin αvβ3‑PP2A complexes activate HDAC5, which deacetylates Runx2, further diminishing its transcriptional potency. This dual inhibition shifts VSMCs from a pro‑calcific, senescent state toward a quiescent contractile phenotype, breaking the feed‑forward loop where elastin degradation fuels calcification and vice‑versa.

Testable Predictions

1. In VSMCs isolated from aged mice, tropoelastin treatment will increase PP2A association with integrin αvβ3 and decrease phospho‑AKT (Ser473) levels.
2. Genetic knockdown of integrin αvβ3 or pharmacological inhibition of PP2A will abolish tropoelastin‑mediated suppression of Runx2 target genes (ALP, OPN, BGLAP).
3. Tropoelastin will reduce SASP factor secretion (IL‑6, IL‑8, MMP‑9) in senescent VSMCs, an effect lost when PP2A is inhibited.
4. Combined tropoelastin delivery with low‑dose OPG will synergistically reduce arterial calcification in aged ApoE‑/‑ mice compared with either monotherapy.

Experimental Design

• In vitro: Culture primary human aortic VSMCs induced to senesce via repeated passaging or H2O2 exposure. Treat with recombinant tropoelastin (± integrin αvβ3 blocking antibody, ± PP2A inhibitor okadaic acid). Assess PP2A‑integrin co‑immunoprecipitation, AKT phosphorylation (Western blot), Runx2 acetylation (immunoprecipitation‑acetyl‑lysine blot), and expression of osteogenic and senescence markers (qPCR, ELISA).
• Ex vivo: Wire‑myography of murine aorta segments to measure stiffness after tropoelastin ± OPG treatment.
• In vivo: Aged ApoE‑/‑ mice receive subcutaneous tropoelastin hydrogel (or placebo) with or without OPG‑Fc fusion protein for 12 weeks. Endpoints: elastin content (Verhoeff‑Van Gieson), calcification burden (von Kossa, micro‑CT), VSMC phenotype (SM‑α‑actin vs Runx2 immunostaining), and circulating SASP cytokines.

Potential Outcomes and Falsification

If tropoelastin fails to increase PP2A‑integrin interaction or does not lower phospho‑AKT/Runx2 activity, the hypothesis is falsified. Conversely, observing the predicted biochemical changes accompanied by reduced calcification and SASP would support the model and suggest a dual‑target strategy to counteract arterial stiffening.

This hypothesis directly links ECM restoration to intracellular signaling senescence and osteogenic switch, offering a mechanistic bridge between the observations that tropoelastin mitigates senescence and that active VSMC osteogenesis drives calcification.